Levetiracetam Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition
Levetiracetam Price Trend, Index and Forecast
Track the latest insights on levetiracetam price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.
Levetiracetam Prices Outlook Q4 2025
- USA: USD 37,260/MT
- China: USD 27,232/MT
- India: USD 34,866/MT
- Germany: USD 43,334/MT
- France: USD 45,492/MT
Levetiracetam Price Chart
Get real-time access to monthly/quarterly/yearly prices Request Sample
During the fourth quarter of 2025, the levetiracetam prices in the USA reached 37,260 USD/MT in December. The market experienced a marginal decline compared to the previous quarter, reflecting balanced supply conditions and moderate procurement activity from pharmaceutical manufacturers. Inventory levels remained comfortable due to steady domestic production and consistent import flows of intermediates. Demand from the generics segment softened slightly as buyers focused on inventory optimization toward year end.
During the fourth quarter of 2025, the levetiracetam prices in China reached 27,232 USD/MT in December. Prices moved lower amid sufficient production rates and stable availability of key intermediates. Domestic manufacturers maintained high operating rates, ensuring ample market supply. Export demand showed moderate fluctuations, particularly from Western markets, which limited upward pricing momentum. Competitive pricing strategies among major suppliers also contributed to the softening trend.
During the fourth quarter of 2025, the levetiracetam prices in India reached 34,866 USD/MT in December. The market reflected a modest downturn driven by adequate production volumes and stable raw material sourcing. Pharmaceutical formulators adopted conservative purchasing strategies, prioritizing existing inventories over fresh bulk orders. Export shipments to regulated markets remained steady but did not provide significant price support.
During the fourth quarter of 2025, the levetiracetam prices in Germany reached 43,334 USD/MT in December. The decline in prices was attributed to steady import arrivals and moderate domestic demand from pharmaceutical producers. Buyers maintained cautious procurement practices amid sufficient stock availability. Stable energy costs and improved supply chain efficiency reduced manufacturing overhead pressures compared to earlier periods.
During the fourth quarter of 2025, the levetiracetam prices in France reached 45,492 USD/MT in December. The market exhibited a slight downward adjustment due to balanced supply demand fundamentals. Import flows from major producing countries remained consistent, ensuring availability for domestic pharmaceutical applications. Procurement activity from generic drug manufacturers moderated toward the end of the year, reflecting inventory alignment strategies.
Levetiracetam Prices Outlook Q3 2025
- USA: USD 37,515/MT
- China: USD 27,443/MT
- India: USD 35,258/MT
- Germany: USD 43,675/MT
- France: USD 45,942/MT
During the third quarter of 2025, the levetiracetam prices in USA reached 37,515 USD/MT in September. Prices increased compared to the previous quarter, supported by improved procurement from pharmaceutical manufacturers and steady prescription demand. Inventory replenishment cycles among distributors strengthened transactional volumes. Supply conditions remained firm due to disciplined production rates and stable raw material sourcing.
During the third quarter of 2025, the levetiracetam prices in China reached 27,443 USD/MT in September. The market experienced an upward movement driven by stronger export inquiries and consistent domestic consumption. Production facilities operated at steady rates, yet supplier confidence improved due to firm overseas demand. Procurement from key importing countries supported price negotiations. Furthermore, stable feedstock availability and efficient logistics facilitated uninterrupted supply chains.
During the third quarter of 2025, the levetiracetam prices in India reached 35,258 USD/MT in September. Prices trended upward amid improved export orders and healthy domestic pharmaceutical demand. Manufacturers reported steady production levels, while procurement of intermediates remained organized and predictable. Increased buying interest from regulated markets supported firmer quotations. Additionally, stable shipping operations ensured timely deliveries, reinforcing supplier confidence.
During the third quarter of 2025, the levetiracetam prices in Germany reached 43,675 USD/MT in September. The upward trend was influenced by stable import costs and resilient pharmaceutical sector demand. Buyers increased procurement volumes to secure supply continuity. Consistent energy pricing and efficient supply chain management supported production economics. Additionally, controlled inventory levels across distribution channels allowed suppliers to maintain stronger negotiating positions.
During the third quarter of 2025, the levetiracetam prices in France reached 45,942 USD/MT in September. The market recorded an increase driven by firm domestic demand and stable import flows. Pharmaceutical manufacturers expanded procurement in response to consistent prescription trends. Supply chain operations remained smooth, minimizing disruptions. Competitive sourcing strategies balanced cost structures while allowing suppliers to maintain higher quotations.
Levetiracetam Prices Outlook Q2 2025
- USA: USD 36,500/MT
- China: USD 26,670/MT
- India: USD 34,118/MT
- Germany: USD 42,560/MT
- France: USD 44,800/MT
During the second quarter of 2025, levetiracetam prices in the USA reached 36,500 USD/MT in June. Levetiracetam prices in the United States remained largely stable during the second quarter of 2025, supported by consistent demand from hospitals, clinics, and outpatient neurology practices. Mild fluctuations were observed due to variable costs of pharmaceutical-grade raw materials and rising energy expenses. Regulatory compliance and quality assurance requirements contributed to overall production costs. Despite occasional logistical bottlenecks, the supply chain remained mostly undisrupted. Market sentiment stayed firm, with levetiracetam prices aligning closely with input costs and stable therapeutic demand, particularly in the treatment of epilepsy and seizure-related disorders.
During the second quarter of 2025, levetiracetam prices in China reached 26,670 USD/MT in June. Levetiracetam prices in China exhibited mild fluctuations, primarily influenced by variable costs of active pharmaceutical ingredients and rising energy prices. Domestic production remained stable, supported by strong local manufacturing infrastructure and consistent demand from hospitals and neurology clinics. However, occasional supply chain disruptions and stricter regulatory controls contributed to modest price volatility. Export conditions and currency fluctuations also played a role in shaping cost dynamics. Despite these pressures, overall market sentiment remained stable, with prices closely aligned to input cost trends and steady therapeutic utilization.
During the second quarter of 2025, levetiracetam prices in India reached 34,118 USD/MT in June. Levetiracetam prices in India remained relatively stable throughout, supported by a strong domestic production base and consistent demand in both the public and private healthcare sectors. Input cost fluctuations, especially for raw materials and energy, introduced minor pricing variability. Regulatory compliance and quality standards added to production overheads, while exports experienced modest logistical delays. Despite these factors, the pricing environment reflected a well-balanced market, with manufacturers adjusting prices in line with material costs and maintaining a steady supply to meet therapeutic demand.
During the second quarter of 2025, levetiracetam prices in Germany reached 42,560 USD/MT in June. Levetiracetam prices showed moderate fluctuations, primarily influenced by variable energy tariffs and compliance-related production expenses. Demand from hospitals and clinics remained consistent, backed by levetiracetam’s established use in epilepsy treatment. While the domestic supply chain remained resilient, import dynamics and currency fluctuations had a slight impact on procurement costs. Environmental and pharmaceutical regulations continued to impact manufacturing margins. Overall, pricing remained firm, with adjustments reflecting changes in input costs and steady clinical utilization.
During the second quarter of 2025, levetiracetam prices in France reached 44,800 USD/MT in June. Levetiracetam prices in France remained largely stable, with slight variations attributed to changes in energy and operational costs. The country’s national health system ensured consistent demand, particularly in neurology departments. Local manufacturers maintained a reliable supply, though minor delays in raw material sourcing introduced temporary pressures. Regulatory obligations related to packaging, safety, and sustainability added to production expenses. Despite these factors, the market-maintained equilibrium, with prices generally aligned to supply chain conditions and steady prescription volumes.
Regional Coverage
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing levetiracetam prices.
Europe Levetiracetam Price Trend
Q4 2025:
In Europe, the levetiracetam price index reflected a modest downward adjustment during the fourth quarter of 2025. Regional markets observed balanced supply conditions supported by consistent imports from Asia and stable domestic production. Pharmaceutical demand remained steady but lacked strong expansion, leading to cautious procurement practices. Energy stability and improved logistics efficiency reduced cost pressures across manufacturing hubs. Competitive supplier positioning within key European economies also limited pricing flexibility, resulting in a controlled and moderate softening trend.
Q3 2025:
In Europe, the levetiracetam price index indicated a firm upward movement. The regional market benefited from resilient demand across major pharmaceutical manufacturing economies, where prescription volumes for antiepileptic therapies remained consistent. Import costs from Asia remained stable, yet firm supplier offers reflected confident market sentiment. Buyers actively participated in restocking cycles following earlier inventory drawdowns, which reinforced procurement volumes and strengthened transactional momentum.
Q2 2025:
In Europe, levetiracetam prices showed mild fluctuations, primarily influenced by varying energy and production costs across the region. Demand remained steady from both public healthcare systems and private providers, driven by its established role in epilepsy management. Countries such as Germany, France, and Italy maintained consistent usage, while their supply chains operated efficiently despite minor logistical challenges. Overall, the pricing environment remained stable, with levetiracetam prices aligning with input costs and sustained therapeutic demand across major European pharmaceutical markets.
This analysis can be extended to include detailed levetiracetam price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
North America Levetiracetam Price Trend
Q4 2025:
In North America, the levetiracetam price index showed a slight decline. The regional market maintained adequate inventory levels supported by reliable import flows and organized distribution networks. Demand from generic drug manufacturers remained stable but subdued toward year end. Improved freight operations and balanced production rates limited supply side volatility. Market sentiment leaned cautious, contributing to marginally softer pricing across the region.
Q3 2025:
In North America, the levetiracetam price index recorded a positive trend. The region experienced steady prescription demand from the neurology segment, encouraging pharmaceutical companies to secure consistent raw material supply. Import flows remained reliable, particularly from Asian producers, ensuring balanced product availability without oversupply conditions. Domestic output operated at stable rates, reinforcing confidence among suppliers and distributors. Buyers moderately increased procurement volumes to replenish inventories and align with anticipated sales cycles.
Q2 2025:
In North America, levetiracetam prices remained steady, supported by stable demand from hospitals and outpatient neurology clinics. The region experienced consistent consumption across the U.S. and Canada, driven by its widespread use in seizure management. Minor pricing fluctuations were attributed to changes in production input costs and regulatory compliance expenses. Supply chains remained largely undisrupted, with generic manufacturers maintaining strong distribution networks. Overall, levetiracetam pricing reflected a balanced market, with rates closely aligned to manufacturing trends and consistent therapeutic demand throughout the quarter.
Specific levetiracetam historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Middle East and Africa Levetiracetam Price Trend
Q4 2025:
As per the levetiracetam price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q3 2025:
The report explores the levetiracetam pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on levetiracetam prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Asia Pacific Levetiracetam Price Trend
Q4 2025:
In Asia Pacific, levetiracetam prices softened moderately. The regional market was characterized by sustained operating rates across leading production hubs, resulting in comfortable inventory levels throughout the supply chain. Manufacturers maintained consistent output to fulfill both domestic and export commitments, which limited supply tightness. Export activity remained uneven, as inquiries from certain Western markets slowed while other destinations maintained regular procurement volumes, prompting suppliers to adopt flexible pricing strategies.
Q3 2025:
In Asia Pacific, levetiracetam prices experienced noticeable strengthening. Strong export demand from Western pharmaceutical markets enhanced supplier leverage, particularly for high quality compliant grades. Domestic pharmaceutical requirements also remained supportive, driven by consistent prescription trends and stable healthcare procurement. Production facilities maintained disciplined operating rates, preventing oversupply and preserving market balance. Manufacturers strategically adjusted offer levels in response to firm overseas inquiries, reinforcing upward pricing momentum.
Q2 2025:
In the Asia Pacific region, levetiracetam prices remained largely stable during the second quarter of 2025, supported by consistent demand from neurological care segments and robust generic manufacturing across countries such as India and China. Moderate fluctuations were observed due to variable raw material and energy costs, as well as currency shifts impacting export margins. Regional pharmaceutical companies maintained steady production and supply, ensuring minimal disruptions to the market. Overall, the pricing environment reflected balanced supply-demand conditions, with levetiracetam prices aligning closely with input cost trends and sustained therapeutic use across major healthcare systems.
This levetiracetam price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Latin America Levetiracetam Price Trend
Q4 2025:
Latin America's levetiracetam market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in levetiracetam prices.
Q3 2025:
Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, levetiracetam index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing levetiracetam pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
Levetiracetam Pricing Report, Market Analysis, and News
IMARC's latest publication, “Levetiracetam Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” presents a detailed examination of the levetiracetam market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of levetiracetam at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed levetiracetam prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting levetiracetam pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.
Levetiracetam Industry Analysis
The global levetiracetam market size reached USD 1.7 Billion in 2025. By 2034, IMARC Group expects the market to reach USD 3.7 Billion, at a projected CAGR of 8.41% during 2026-2034. Growth in the levetiracetam market is driven by rising neurological disorder diagnoses, expanding generic drug penetration, and increasing healthcare access in emerging economies.
Latest News and Developments:
- August 2025: An FDA funded NEOLEV3 clinical trial advanced a stratified treatment strategy for neonatal seizures using levetiracetam before phenobarbital. The study evaluated escalating levetiracetam doses to determine the maximum tolerated level, with infants unresponsive to standard dosing randomized to higher-dose levetiracetam or phenobarbital. Phase 1 enrolled 78 neonates and confirmed safety up to 90 mg/kg without unexpected adverse events. Phase 2 remained ongoing, with early findings showing seizure cessation at 120 mg/kg, supporting safety and potential efficacy of higher dosing.
Product Description
Levetiracetam is an antiepileptic drug used to treat various types of seizures in individuals with epilepsy. It is commonly prescribed for partial onset seizures, myoclonic seizures, and generalized tonic colonic seizures in both adults and children. Levetiracetam works by modulating neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing brain electrical activity and reducing seizure frequency. It is available in multiple formulations, including oral tablets, extended release tablets, oral solution, and intravenous injection, allowing for flexible administration based on patient needs.
Known for its favorable safety profile, levetiracetam is generally well tolerated, with common side effects including dizziness, fatigue, and mood changes. It is often preferred for its minimal drug interactions and ease of dose adjustment. Due to its efficacy and tolerability, levetiracetam has become a widely used first line therapy in seizure management and is frequently included in long term epilepsy treatment plans.
Report Coverage
| Key Attributes | Details |
|---|---|
| Product Name | Levetiracetam |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Levetiracetam Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s report presents a detailed analysis of levetiracetam pricing, covering global and regional trends, spot prices at key ports, and a breakdown of FOB and CIF prices.
- The study examines factors affecting levetiracetam price trend, including input costs, supply-demand shifts, and geopolitical impacts, offering insights for informed decision-making.
- The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
- IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The levetiracetam price charts ensure our clients remain at the forefront of the industry.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Request Customization
Inquire Before Buying
Speak to an Analyst
Request Brochure
Benefits of Customization
- Personalize this research
- Triangulate with your data
- Get data as per your format and definition
- Gain a deeper dive into a specific application, geography, customer, or competitor
- Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-201-971-6302
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
.webp)
.webp){kind=logo}
Why Choose Us
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
Robust Methodologies & Extensive Resources
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Subscription-Based Databases
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Primary Research-Driven Insights
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
Extensive Secondary Research
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.